Program Schedule

253
Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter baumannii from New York City

Session: Poster Abstract Session: Antimicrobial Resistance: Novel Agents and Approaches to Gram-negative Infections
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Background: Multidrug-resistant Gram-negative bacteria have become established in hospitals in New York City. Novel antibiotics are sorely needed to treat infections due to multidrug-resistant strains. Eravacycline is a novel fluorocycline, and is not affected by common mechanisms leading to tetracycline resistance. In this study we examine the activity of eravacycline against Gram-negative pathogens from New York City, a region plagued by MDR strains.

Methods: From November 2013 through January 2014, single patient bacterial isolates were gathered from 11 hospitals in Brooklyn and Queens, NY. Isolates underwent susceptibility testing by dilution techniques according to CLSI methodology. Cephalosporin-resistant isolates were also screened by PCR for the presence of blaKPC.

Results: Among 2866 isolates of E. coli, 87% were susceptible to cephalosporins and 99.8% to carbapenems; two possessed blaKPC. For 944 Klebsiella pneumoniae, 67% were susceptible to cephalosporins and 86% to carbapenems; 13% possessed blaKPC. For 216 Enterobacter spp., 75% were susceptible to cephalosporins and 95% to carbapenems; 3% possessed blaKPC. For 158 Acinetobacter baumannii, 34% were susceptible to cephalosporins and 31% to carbapenems. The susceptibility results for tetracycline and eravacycline are listed in the Table.

 

 

MIC50

MIC90

Range

Percent susceptible

 

μg/ml

 

E. coli (n=2866)

Tetracycline

4

>16

≤0.25 - >16

59%

Eravacycline

0.12

0.5

≤0.015 - 4

 

K. pneumoniae (n=944)

Tetracycline

4

>16

1 - >16

68%

Eravacycline

0.25

1

≤0.06 - 8

 

Enterobacter spp. (n=216)

Tetracycline

2

16

≤0.25 - >16

78%

Eravacycline

0.5

1

≤0.12 - 2

 

A. baumannii (n=158)

Tetracycline

>16

>16

2 - >16%

10%

Tigecycline

2

>2

≤0.06 ->2

66%

Eravacycline

0.5

1

≤0.015 - 4

 

Among 125 isolates of K. pneumoniae with blaKPC, the MIC50 and MIC90 values for eravacycline were 0.5 and 1.0 μg/ml, respectively. For 96 isolates of A. baumannii resistant to carbapenems, the MIC50 and MIC90values were 0.5 and 2 μg/ml, respectively.

Conclusion: Eravacycline is a novel antibacterial agent with excellent in vitro activity against E. coli, K. pneumoniae, Enterobacter spp. and A. baumannii, including multidrug-resistant isolates.

Marie Abdallah, MD1, Olawole Olafisoye, MD1, Christopher Cortes, MD2, Carl Urban, PhD3, David Landman, MD4 and John Quale, MD4, (1)Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, NY, (2)Infectious Diseases, New York Hospital Queens, Flushing, NY, (3)Infectious Disease, New York Hospital Queens, Flushing, NY, (4)Medicine, SUNY Downstate Medical Center, Brooklyn, NY

Disclosures:

M. Abdallah, None

O. Olafisoye, None

C. Cortes, None

C. Urban, Pfizer: Speaker's Bureau, Speaker honorarium
Cubist: Speaker's Bureau, Speaker honorarium

D. Landman, Tetraphase: Research Contractor, Research grant
Achaogen: Research Contractor, Research grant

J. Quale, Tetraphase: Research Contractor, Research grant
Achaogen: Research Contractor, Research grant

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek